The initial indication is reduction of post-operative pain using AmacaThera’s (formerly Hammock Therapeutics) hydrogel in combination with approved anaesthetics. Currently available delivery vehicles are designed with the sole purpose of delivering a drug. AmacaThera’s delivery vehicle has been designed to not only deliver the drug but also to promote healing.

In February 2021, AmacaThera Inc. closed a CDN $10.3 million Series A round of financing with Lumira Ventures, Viva BioInnovator, Sprout BioVentures, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS Investment Accelerator Fund (IAF). Read press release here.